drugset / Trial / NCT07364487

This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis

NCT07364487

Phase 0 Withdrawn Huashan Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label,early-stage exploratory clinical study to evaluate the safety and preliminary efficacy of GC012F CAR T cell injection in Multiple Sclerosis subjects.

Timeline

Start
2026-01-26
Primary completion
2026-03-25
Completion
2026-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject GC012F Cell therapy Intravenous

Indications